אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - sodium bicarbonate, quantity: 2.1 g/l; sodium lactate, quantity: 1.68 g/l; magnesium chloride hexahydrate, quantity: 51 mg/l; glucose monohydrate, quantity: 25 g/l (equivalent: glucose, qty 22.7 g/l); calcium chloride dihydrate, quantity: 0.184 g/l; sodium chloride, quantity: 5.38 g/l - solution, dialysis - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - physioneal 40 is indicated for use in peritoneal dialysis in patients with acute or chronic renal failure.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - glucose monohydrate, quantity: 15 g/l (equivalent: glucose, qty 13.6 g/l); sodium bicarbonate, quantity: 2.1 g/l; sodium chloride, quantity: 5.38 g/l; magnesium chloride hexahydrate, quantity: 51 mg/l; sodium lactate, quantity: 1.68 g/l; calcium chloride dihydrate, quantity: 0.184 g/l - solution, dialysis - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - physioneal 40 is indicated for use in peritoneal dialysis in patients with acute or chronic renal failure.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - icodextrin, quantity: 75 g/l; sodium chloride, quantity: 5.4 g/l; sodium lactate, quantity: 4.5 g/l; calcium chloride dihydrate, quantity: 257 mg/l; magnesium chloride hexahydrate, quantity: 51 mg/l - solution, dialysis - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - indicated as "an alternative osmotic agent in dialysis solution for the long dwell exchange in patients treated with peritoneal dialysis."

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - icodextrin, quantity: 75 g/l; sodium chloride, quantity: 5.4 g/l; sodium lactate, quantity: 4.5 g/l; calcium chloride dihydrate, quantity: 257 mg/l; magnesium chloride hexahydrate, quantity: 51 mg/l - solution, dialysis - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - indicated as "an alternative osmotic agent in dialysis solution for the long dwell exchange in patients treated with peritoneal dialysis."

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - sodium chloride, quantity: 5.39 g/l; calcium chloride dihydrate, quantity: 0.183 g/l; magnesium chloride hexahydrate, quantity: 0.0508 g/l; sodium lactate, quantity: 4.48 g/l; glucose monohydrate, quantity: 5.5 g/l - solution, dialysis - excipient ingredients: sodium hydroxide; water for injections - indications: use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis.

מלטה - אנגלית - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - gliclazide - tablet - gliclazide - drugs used in diabetes

ישראל - אנגלית - Ministry of Health

medici medical ltd, israel - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); pertactin (prn); pertussis toxoid vaccine; poliovirus type 1; poliovirus type 2; poliovirus type 3; prp of haemophilus infl. type b; tetanus toxoid - suspension for injection - pertactin (prn) 3 mcg ml; diphtheria toxoid 15 lf ml; tetanus toxoid 5 lf ml; pertussis toxoid vaccine 20 mcg ml; filamentous haemagglutinin (fha) 20 mcg ml; fimbrae tupes 2 + 3 (fim) 5 mcg ml; poliovirus type 1 40 du ml; poliovirus type 2 8 du ml; poliovirus type 3 32 du ml; prp of haemophilus infl. type b 10 mcg ml - bacterial and viral vaccines, combined - pediacel is indicated for immunization of children at or above the age of 2 months and as a booster in children up to their 7th birthday against diphtheria, tetanus, whooping cough, poliomyelitis and invasive haemophilus influenzae type b disease. in infants, three infectons are to be given intramuscularly at 2, 4 and 6 months of age followed by a booster at 18 months of age. children who have had pertusis, tetanus, diphtheria or haemophilus influenzae type b invasive disease should still be immunized since these clinical infections do not always confer immunity. children who have had natural pertussis can continue to receive pertussis - containing vaccines. human immunodeficiency virus (hiv) infected persons hiv- infected individuals, both asymptomatic and symptomatic, should be immunized with pediacel vaccine according to standard schedules.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 12.5mg;  ; metformin hydrochloride 1000mg;   - film coated tablet - 12.5mg/1000mg - active: empagliflozin 12.5mg   metformin hydrochloride 1000mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry purple 02b200006 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 12.5mg;  ; metformin hydrochloride 500mg;   - film coated tablet - 12.5mg/500mg - active: empagliflozin 12.5mg   metformin hydrochloride 500mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry pink 02b20004 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 12.5mg;  ; metformin hydrochloride 850mg;   - film coated tablet - 12.5mg/850mg - active: empagliflozin 12.5mg   metformin hydrochloride 850mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry pink 02b240006 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.